Cipla reported a strong second quarter with a 4% sequential revenue increase to INR 7,404 crore and a net profit of INR 878 crore. Growth was bolstered by a record-breaking performance in the 'One India' business and rising revenues in North America. Management remains optimistic, reiterating guidance for a $1 billion annualized run rate in the U.S. market, supported by healthy cash reserves and a focus on complex drug launches.
Cipla Q2 Results: Steady Growth Driven by India and U.S. Markets
Revenue grew to INR 7,404 crore, with a net profit of INR 878 crore reported for the quarter.
Reader Takeaway: Strong India business performance and U.S. pipeline progress drive revenue, while Pithampur regulatory observations remain a key watchpoint.
What just happened
Cipla reported a sequential revenue growth of 4% for Q2 FY27, reaching INR 7,404 crore. The company achieved an EBITDA margin of 18.7%, benefiting from an improved product mix. The PAT stood at INR 878 crore, reflecting stable operational efficiency despite increased investment in R&D, which totalled INR 423 crore during the period.
Why this matters
The company’s core 'One India' business reached its highest-ever quarterly revenue, growing 12% year-on-year. Branded prescriptions, particularly in chronic therapies like respiratory and antidiabetes, continue to provide a solid foundation for earnings. Simultaneously, the North American business reached $172 million in revenue, putting the firm on track for its target of a $1 billion annualized run rate by the end of the fiscal year.
Strategic Developments
Cipla is accelerating its U.S. pipeline through key partnerships, including a deal with CTTQ for a novel oncology drug and a biosimilar collaboration with Qilu Pharmaceutical. The company successfully secured approvals for generic versions of Ventolin and Advair, with three additional major launches planned for the U.S. market this year.
Risks to watch
Regulatory scrutiny persists as the Pithampur facility in India received seven observations in a recent FDA Form 483 inspection. Management is currently addressing these concerns. Meanwhile, the Invagen facility in New York holds a VAI classification, and another Long Island unit cleared a recent GMP inspection without observations.
Context metrics
Cipla maintains a robust balance sheet with net cash equivalents of INR 9,823 crore against minimal debt of INR 699 crore. This liquidity is earmarked for potential acquisitions of complex assets in developed markets.
What to track next
Investors should monitor the resolution of the Pithampur facility observations and the progress of upcoming U.S. launches to ensure the $1 billion run rate goal remains achievable.